Spondyloarthritis & psoriatic arthritis
Difficult-to-treat axial spondyloarthritis is associated with psoriasis, peripheral involvement and comorbidities: results of an observational nationwide study
Authors' conclusion
D2T-axSpA affects one in five patients exposed to bDMARDs in this national cohort. D2T-axSpA is more common in women and patients with peripheral involvement and/or comorbidities.
Study context
- Population
- French patients newly receiving long-term illness benefits for ankylosing spondylitis (AS), 2010–2013; follow-up to 31 December 201810,798 received ≥1 bDMARD
- Participants
- 22,932 patients
- Exposure
- Difficult-to-treat axial spondyloarthritis (D2T-axSpA) vs non-D2T-axSpA patients who had received at least one b/tsDMARD
- D2T-axSpAn = 2,115
- Outcome
- Cumulative incidence of D2T-axSpA and associated factors
Methodological detailsnationwide, French National Medico-Administrative Database (SNDS), multivariate logistic regression, competing risk analysis
- Nationwide
- French National Medico-Administrative Database (SNDS)
- Multivariate logistic regression
- Competing risk analysis
Main finding
As reported in the abstract
Cumulative incidence of D2T-axSpA among patients who received at least one bDMARD · end of follow-up (31 December 2018)
D2T-axSpA
19.59%
2115
- In multivariate analysis, D2T-axSpA significantly associated with female gender, peripheral involvement, psoriasis, hypertension and depression
- P < 0.001 for each case
Observational data: associations, not effects.
Further findings
Exposure to b/tsDMARDs
- Received at least one bDMARD
- 10 798 (47.08%)
- Received tsDMARD
- 0
Safety
| Outcome | P value |
|---|---|
| Incidence of MACE and death, D2T-axSpA vs non-D2T-axSpAD2T-axSpA vs non-D2T-axSpA · MACE; no difference · competitive risk analysis | P = 0.92 |
| Incidence of MACE and death, D2T-axSpA vs non-D2T-axSpAD2T-axSpA vs non-D2T-axSpA · death; no difference · competitive risk analysis | P = 0.87 |
Original publication
Difficult-to-treat axial spondyloarthritis is associated with psoriasis, peripheral involvement and comorbidities: results of an observational nationwide study. RMD Open. Published 23 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →